Bowden S - Search Results

1

TCD8 response in diverse outcomes of recurrent exposure to hepatitis C virus.

Bharadwaj M, Thammanichanond D, Aitken CK, Moneer S, Drummer HE, Tracy S, Holdsworth R, Bowden S, Jackson D, Hellard M, Torresi J, McCluskey J. Bharadwaj M, et al. Among authors: bowden s. Immunol Cell Biol. 2009 Aug-Sep;87(6):464-72. doi: 10.1038/icb.2009.24. Epub 2009 May 12. Immunol Cell Biol. 2009. PMID: 19434069

2

Investigation of infection control practices and knowledge of hepatitis C among body-piercing practitioners.

Hellard M, Aitken C, Mackintosh A, Ridge A, Bowden S. Hellard M, et al. Among authors: bowden s. Am J Infect Control. 2003 Jun;31(4):215-20. doi: 10.1067/mic.2003.61. Am J Infect Control. 2003. PMID: 12806358

3

Indications of immune protection from hepatitis C infection.

Aitken CK, Bowden S, Hellard M, Crofts N. Aitken CK, et al. Among authors: bowden s. J Urban Health. 2004 Mar;81(1):58-60. doi: 10.1093/jurban/jth088. J Urban Health. 2004. PMID: 15047784 Free PMC article.

4

Change in hepatitis C virus genotype in injecting drug users.

Aitken C, McCaw R, Jardine D, Bowden S, Higgs P, Nguyen O, Crofts N, Hellard M. Aitken C, et al. Among authors: bowden s. J Med Virol. 2004 Dec;74(4):543-5. doi: 10.1002/jmv.20212. J Med Virol. 2004. PMID: 15484265

5

Detection of multiple hepatitis C virus genotypes in a cohort of injecting drug users.

Bowden S, McCaw R, White PA, Crofts N, Aitken CK. Bowden S, et al. J Viral Hepat. 2005 May;12(3):322-4. doi: 10.1111/j.1365-2893.2005.00592.x. J Viral Hepat. 2005. PMID: 15850474

6

A study to investigate the impact of the initiation of highly active antiretroviral therapy on the hepatitis C virus viral load in HIV/HCV-coinfected patients.

Mijch A, Sasadeusz J, Hellard M, Dunne M, McCaw R, Bowden S, Gowans EJ. Mijch A, et al. Among authors: bowden s. Antivir Ther. 2005;10(2):277-84. Antivir Ther. 2005. PMID: 15865222

7

Differences in the social networks of ethnic Vietnamese and non-Vietnamese injecting drug users and their implications for blood-borne virus transmission.

Aitken CK, Higgs P, Bowden S. Aitken CK, et al. Among authors: bowden s. Epidemiol Infect. 2008 Mar;136(3):410-6. doi: 10.1017/S0950268807008679. Epub 2007 May 17. Epidemiol Infect. 2008. PMID: 17506918 Free PMC article.

8

Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.

Boo I, Fischer AE, Johnson D, Chin R, Giourouki M, Bharadwaj M, Bowden S, Torresi J, Drummer H. Boo I, et al. Among authors: bowden s. J Clin Virol. 2007 Aug;39(4):288-94. doi: 10.1016/j.jcv.2007.04.019. Epub 2007 Jun 14. J Clin Virol. 2007. PMID: 17569577

9

Failure of lamivudine to reverse hepatitis B virus-associated changes in ERK, Akt and cell cycle regulatory proteins.

Chin R, Earnest-Silveira L, Koeberlein B, Franz S, Zentgraf H, Bowden S, Bock CT, Torresi J. Chin R, et al. Among authors: bowden s. Antivir Ther. 2008;13(2):221-30. Antivir Ther. 2008. PMID: 18505173

10

Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.

Miller ER, Hellard ME, Bowden S, Bharadwaj M, Aitken CK. Miller ER, et al. Among authors: bowden s. J Infect. 2009 May;58(5):375-82. doi: 10.1016/j.jinf.2009.02.014. Epub 2009 Mar 27. J Infect. 2009. PMID: 19328555

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

516 results

Search Page

Filters